Navigation Links
Rosalind™ Launches the Next Era of Genomics
Date:10/12/2017

OnRamp BioInformatics (https://www.onramp.bio/) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers to analyze and interpret datasets, by eliminating all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a major contribution to the discovery of the double-helix structure of DNA with her famous photograph 51, OnRamp’s Rosalind™ platform aims to simplify the practice of genomic data interpretation.

“The platform puts the researcher into the driver’s seat of data analysis,” says Tim Wesselman, CEO and Founder of OnRamp.

“Rosalind™ will democratize bioinformatics by broadly expanding access to genomic and proteomic technologies for cancer research, precision medicine and sustainable agriculture.”

Over the past two decades, research technologies such as next-generation sequencing, microarray, and mass-spectrometry have become mainstream. While these technologies have driven significant medical advances, their full potential to transform personalized medicine remains constrained by the unprecedented volume and complexities of the data being generated.

OnRamp’s Rosalind™ overcomes a number of the limitations found in existing data analysis tools:

Complex tools require highly-trained bioinformaticians who are constantly overextended and in high demand. These skilled bioinformaticians spend valuable time on manual processes that could be automated so they can focus on exciting challenges and new frontiers. Service providers and kit companies lack scalable analysis solutions for customers using their products. Pharma experts continually articulate their need for robust, highly scalable data management solutions which enable them to securely and efficiently store, track, and share data.

“Top cancer research institutions have been vocal about their frustrations,” says Wesselman. “Currently, they spend thousands of dollars sequencing samples, only to receive datasets that require weeks and months of additional analysis. Rosalind™ delivers these analysis results within hours, not weeks.”

The self-guided Rosalind™ platform empowers researchers to analyze their own data. For the first time, researchers performing large-scale genomics studies across a range of fields (including drug development, precision medicine, and agri-business) can rapidly and dynamically explore and interpret their own data, accelerating their next phase of research while saving time and money.

Rosalind™ guides the researcher through the entire process, from experimental design to interpretation, for analyses including transcriptomics and epigenetics.

OnRamp CTO Jean Lozach explains how the responsive, interactive interfaces allows researchers to create their own analyses from start to finish:

“Researchers define their experimental design and upload raw data sets. Rosalind™ then performs scalable backend analyses and interpretation to generate biologically relevant results that meaningfully advance their research. This transformative experience restores the element of excitement and provides a measurable increase in productivity.”

“Advanced bioinformaticians deserve all of the credit for building state-of-the-art applications to analyze genomic, proteomic, and microarray data,” Lozach continues. “While these tools remain the lifeline of genomic analysis, more simplified user experiences are now required to empower today’s cancer biologists to focus on their research application, not which software application to use.”

Tim Wesselman concurs:

“We believe that widespread adoption of automated bioinformatic technologies will dramatically lower research costs and, ultimately, put more focus back on what to do with results, not how to get to them.”

“With Rosalind™, we’ve evolved genomic data analysis and interpretation, so our customers can get back to revolutionizing the organic world.”

About OnRamp BioInformatics
Based in the Genomics Capital of San Diego, OnRamp BioInformatics provides software and systems to streamline and simplify the analysis, data management and storage of large-scale genomic datasets so that biologists, researchers and drug developers can harness the full potential of DNA sequencing. Follow us on Twitter (@OnRampBio), or visit us at http://www.onramp.bio.

About Rosalind Franklin
Born in London, England in 1920, Rosalind Elsie Franklin studied chemistry at Cambridge, earned a research fellowship and a Ph.D. for study that aided the British war effort. Franklin went on to significantly advance our understanding of X-ray crystallography and was instrumental in the discovery of the DNA double helix. She died of ovarian cancer in 1958 at the age of 37, her contribution to the discovery of the helical structure of DNA going largely unrecognized during her lifetime.

Read the full story at http://www.prweb.com/releases/2017/10/prweb14796846.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Rosalind™ Launches the Next Era of Genomics
2. LabRoots Launches Month-long Campaign in Efforts to Push Breast Cancer Research Forward
3. IS&T Launches New Journal of Perceptual Imaging
4. Institute of Food Safety and Health (IFSH) Launches Food Processing Center of Excellence in Chicago at Annual Meeting
5. Heritage Biologics launches innovative HBnow virtual care program
6. AcCELLerated Biologics Launches Distribution Partnership with CEP-Topical Gear T:25 Technology
7. BioPharma Institute Launches 5 Top U.S. Pharmaceutical & Clinical Research Industry Regulatory Compliance Courses as Parent Company Celebrates 20th Anniversary
8. The Refinery Launches 2nd Annual “Fueling the Growth” Competition
9. RoosterBio Launches New cGMP Stem Cell Product Portfolio, Maintaining Unwavering Commitment to Driving the Explosive Regenerative Medicine Industry
10. Jenway Launches Genova Bio Spectrophotometer for Life Science Applications
11. LabRoots Launches Fall STEM Scholarship for College Students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):